Haverford Financial Services Inc. reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 6.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,128 shares of the company's stock after selling 3,851 shares during the period. Johnson & Johnson accounts for about 2.5% of Haverford Financial Services Inc.'s investment portfolio, making the stock its 18th largest holding. Haverford Financial Services Inc.'s holdings in Johnson & Johnson were worth $8,117,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Johnson & Johnson during the fourth quarter valued at $1,339,878,000. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 228.1% in the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock worth $549,223,000 after acquiring an additional 2,356,359 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Johnson & Johnson by 11.4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock valued at $2,721,355,000 after buying an additional 1,729,281 shares during the period. Amundi boosted its position in Johnson & Johnson by 16.2% in the fourth quarter. Amundi now owns 11,930,183 shares of the company's stock worth $1,698,984,000 after purchasing an additional 1,660,458 shares during the last quarter. Finally, Holocene Advisors LP bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at about $225,040,000. Institutional investors own 69.55% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on JNJ shares. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a report on Monday, March 10th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.33.
View Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling
In other news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.
Johnson & Johnson Trading Down 1.1 %
JNJ stock traded down $1.74 during midday trading on Tuesday, reaching $161.55. 2,234,239 shares of the company traded hands, compared to its average volume of 9,144,597. The firm has a market capitalization of $389.31 billion, a price-to-earnings ratio of 24.30, a P/E/G ratio of 2.56 and a beta of 0.47. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business has a 50 day moving average of $157.37 and a 200-day moving average of $156.16. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period last year, the company earned $2.29 earnings per share. Johnson & Johnson's revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is currently 74.59%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
